Adelaide Research & Scholarship: Search

Search

Results 1-10 of 16 (Search time: 0.002 seconds).

previous
1
2
next

Item hits:

Preview	Issue Date	Title	Author(s)
	2009	Dasatinib or high-dose Imatinib for chronic-phase chronic myeloid leukemia resistant to Imatinib at a dose of 400 to 600 milligrams daily. Two-year follow-up of a randomized phase 2 study (START-R)	Kantarjian, H.; Pasquini, R.; Levy, V.; Jootar, S.; Holowiecki, J.; Hamerschlak, N.; Hughes, T.; Bleickardt, E.; Dejardin, D.; Cortes, J.; Shah, N.
	2009	Dasatinib treatment for Philadelphia chromosome-positive Leukemias: practical considerations	Khoury, H.; Guilhot, F.; Hughes, T.; Kim, D.; Cortes, J.
	2009	A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph plus CML or relapsed/refractory Ph plus ALL	Tojo, A.; Usuki, K.; Urabe, A.; Maeda, Y.; Kobayashi, Y.; Jinnai, I.; Ohyashiki, K.; Nishimura, M.; Kawaguchi, T.; Tanaka, H.; Miyamura, K.; Miyazaki, Y.; Hughes, T.; Branford, S.; Okamoto, S.; Ishikawa, J.; Okada, M.; Usui, N.; Tanii, H.; Amagasaki, T.; et al.
	2009	Genomic translocation breakpoint sequences are conserved in BCR-ABL1 cell lines despite the presence of amplification	Ross, D.; Schafranek, L.; Hughes, T.; Nicola, M.; Branford, S.; Score, J.
	2009	Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo	Fraser, C.; Blake, S.; Diener, K.; Lyons, A.; Brown, M.; Hughes, T.; Hayball, J.
	2009	Predicting the response of CML patients to tyrosine kinase inhibitor therapy	White, D.; Hughes, T.
	2009	Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia	Hochhaus, A.; O'Brien, S.; Guilhot, F.; Druker, B.; Branford, S.; Foroni, L.; Goldman, J.; Muller, M.; Radich, J.; Rudoltz, M.; Mone, M.; Gathmann, I.; Hughes, T.; Larson, R.
	2009	Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value	Hochhaus, A.; Muller, M.; Radich, J.; Branford, S.; Kantarjian, H.; Hanfstein, B.; Rousselot, P.; Kim, D.; Lipton, J.; Bleickhardt, E.; Lambert, A.; Hughes, T.
	2009	Clinical strategies to achieve an early and successful response to tyrosine kinase inhibitor therapy	Hughes, T.; Hochhaus, A.
	2009	Dasatinib inhibits the secretion of TNF-α following TLR stimulation in vitro and in vivo	Fraser, C.; Lousberg, E.; Kumar, R.; Hughes, T.; Diener, K.; Hayball, J.